BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 19643665)

  • 1. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology.
    Vereecke L; Beyaert R; van Loo G
    Trends Immunol; 2009 Aug; 30(8):383-91. PubMed ID: 19643665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downstream activation of NF-κB in the EDA-A1/EDAR signalling in Sjögren's syndrome and its regulation by the ubiquitin-editing enzyme A20.
    Sisto M; Barca A; Lofrumento DD; Lisi S
    Clin Exp Immunol; 2016 May; 184(2):183-96. PubMed ID: 26724675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic relationships between A20/TNFAIP3, chronic inflammation and autoimmune disease.
    Vereecke L; Beyaert R; van Loo G
    Biochem Soc Trans; 2011 Aug; 39(4):1086-91. PubMed ID: 21787353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The seventh zinc finger motif of A20 is required for the suppression of TNF-α-induced apoptosis.
    Yamaguchi N; Yamaguchi N
    FEBS Lett; 2015 May; 589(12):1369-75. PubMed ID: 25911380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant Low Expression of A20 in Tumor Necrosis Factor-α-stimulated SLE Monocytes Mediates Sustained NF-κB Inflammatory Response.
    Shi X; Qian T; Li M; Chen F; Chen Y; Hao F
    Immunol Invest; 2015; 44(5):497-508. PubMed ID: 26107748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABINs: A20 binding inhibitors of NF-kappa B and apoptosis signaling.
    Verstrepen L; Carpentier I; Verhelst K; Beyaert R
    Biochem Pharmacol; 2009 Jul; 78(2):105-14. PubMed ID: 19464428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An enhancer element harboring variants associated with systemic lupus erythematosus engages the TNFAIP3 promoter to influence A20 expression.
    Wang S; Wen F; Wiley GB; Kinter MT; Gaffney PM
    PLoS Genet; 2013; 9(9):e1003750. PubMed ID: 24039598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains.
    Düwel M; Welteke V; Oeckinghaus A; Baens M; Kloo B; Ferch U; Darnay BG; Ruland J; Marynen P; Krappmann D
    J Immunol; 2009 Jun; 182(12):7718-28. PubMed ID: 19494296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained NF-kappaB activity in chronic lymphocytic leukemia is independent of genetic and epigenetic alterations in the TNFAIP3 (A20) locus.
    Frenzel LP; Claus R; Plume N; Schwamb J; Konermann C; Pallasch CP; Claasen J; Brinker R; Wollnik B; Plass C; Wendtner CM
    Int J Cancer; 2011 May; 128(10):2495-500. PubMed ID: 20669229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression, biological activities and mechanisms of action of A20 (TNFAIP3).
    Verstrepen L; Verhelst K; van Loo G; Carpentier I; Ley SC; Beyaert R
    Biochem Pharmacol; 2010 Dec; 80(12):2009-20. PubMed ID: 20599425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A20: linking a complex regulator of ubiquitylation to immunity and human disease.
    Ma A; Malynn BA
    Nat Rev Immunol; 2012 Nov; 12(11):774-85. PubMed ID: 23059429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single nucleotide polymorphisms at the TNFAIP3/A20 locus and susceptibility/resistance to inflammatory and autoimmune diseases.
    Mele A; Cervantes JR; Chien V; Friedman D; Ferran C
    Adv Exp Med Biol; 2014; 809():163-83. PubMed ID: 25302371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A20: central gatekeeper in inflammation and immunity.
    Coornaert B; Carpentier I; Beyaert R
    J Biol Chem; 2009 Mar; 284(13):8217-21. PubMed ID: 19008218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease.
    Zhou Q; Wang H; Schwartz DM; Stoffels M; Park YH; Zhang Y; Yang D; Demirkaya E; Takeuchi M; Tsai WL; Lyons JJ; Yu X; Ouyang C; Chen C; Chin DT; Zaal K; Chandrasekharappa SC; Hanson EP; Yu Z; Mullikin JC; Hasni SA; Wertz IE; Ombrello AK; Stone DL; Hoffmann P; Jones A; Barham BK; Leavis HL; van Royen-Kerkof A; Sibley C; Batu ED; Gül A; Siegel RM; Boehm M; Milner JD; Ozen S; Gadina M; Chae J; Laxer RM; Kastner DL; Aksentijevich I
    Nat Genet; 2016 Jan; 48(1):67-73. PubMed ID: 26642243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A20 in inflammation and autoimmunity.
    Catrysse L; Vereecke L; Beyaert R; van Loo G
    Trends Immunol; 2014 Jan; 35(1):22-31. PubMed ID: 24246475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear factor-kappaB regulates beta-cell death: a critical role for A20 in beta-cell protection.
    Liuwantara D; Elliot M; Smith MW; Yam AO; Walters SN; Marino E; McShea A; Grey ST
    Diabetes; 2006 Sep; 55(9):2491-501. PubMed ID: 16936197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proinflammatory mediators alter expression of nuclear factor kappa B-regulating deubiquitinases in sinonasal epithelial cells.
    Li P; Wang Y; Turner JH
    Int Forum Allergy Rhinol; 2015 Jul; 5(7):583-9. PubMed ID: 25907801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular basis for the unique deubiquitinating activity of the NF-kappaB inhibitor A20.
    Lin SC; Chung JY; Lamothe B; Rajashankar K; Lu M; Lo YC; Lam AY; Darnay BG; Wu H
    J Mol Biol; 2008 Feb; 376(2):526-40. PubMed ID: 18164316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent inactivation of A20 in B-cell lymphomas.
    Kato M; Sanada M; Kato I; Sato Y; Takita J; Takeuchi K; Niwa A; Chen Y; Nakazaki K; Nomoto J; Asakura Y; Muto S; Tamura A; Iio M; Akatsuka Y; Hayashi Y; Mori H; Igarashi T; Kurokawa M; Chiba S; Mori S; Ishikawa Y; Okamoto K; Tobinai K; Nakagama H; Nakahata T; Yoshino T; Kobayashi Y; Ogawa S
    Nature; 2009 Jun; 459(7247):712-6. PubMed ID: 19412163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immune regulation role of A20 and its clinical significance].
    Li YQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):851-6. PubMed ID: 21867600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.